Compare TUYA & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TUYA | EYPT |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2021 | 2005 |
| Metric | TUYA | EYPT |
|---|---|---|
| Price | $2.42 | $13.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $3.49 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 1.8M | 1.8M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 4.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $13.29 | N/A |
| Revenue Next Year | $14.65 | $965.51 |
| P/E Ratio | $27.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.87 | $3.91 |
| 52 Week High | $3.95 | $19.11 |
| Indicator | TUYA | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 38.49 |
| Support Level | $2.29 | $11.88 |
| Resistance Level | $2.44 | $14.24 |
| Average True Range (ATR) | 0.11 | 1.13 |
| MACD | -0.01 | -0.44 |
| Stochastic Oscillator | 32.73 | 9.80 |
Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers innovative physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It also provides a complete, open, and neutral global AIoT ecosystem. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.